Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 1, 2019Therapeutic Advances in HematologyOpen Access

Management of myelodysplastic syndromes after failure of response to hypomethylating agents

View Full Paper
Ask AI
Bookmark
Share

Authors

AGAngela Gil-PerezGMGuillermo Montalban‐Bravo

Discussion

Loading...

Member takes

Overview

Review highlights treatment options for myelodysplastic syndromes after failure of hypomethylating agents, suggesting personalized approaches and new therapies.

Key Points

  • This review aims to explore management strategies for myelodysplastic syndromes in patients who do not respond to hypomethylating agents.
  • Examined the role of hypomethylating agents in treatment and their failure rates.
  • Discussed emerging therapies targeting resistant myelodysplastic syndromes.
  • Evaluated personalized treatment approaches, including allogenic stem-cell transplantation.
  • Around 50% of patients respond to hypomethylating agents, with loss of response within 2 years.
  • New therapies include BCL2 protein inhibitors, immune-checkpoint inhibitors, and targeted agents for specific genetic mutations.
  • Allogeneic stem-cell transplantation remains the only potential curative option.

Cite This Study

Gil-Perez et al. (2019) studied this question.

synapsesocial.com/papers/6a1e7dff09554abc3868e115https://doi.org/10.1177/2040620719847059
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT12009 · 781 citations
  2. 2Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care2017 · 16 citations
  3. 3Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome2017 · 99 citations
  4. 4TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients2014 · 562 citations
  5. 5Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation2016 · 259 citations